Name: Homology Modeling of Human Nk-1 Receptor and Docking Study: Structure Based Drug Design (en Inglés)
Price: 242665.00 COP
Availability: InStock
Author: Manish K. Gupta; Viney Kumar
ISBN: 9783659804205

portada Homology Modeling of Human Nk-1 Receptor and Docking Study: Structure Based Drug Design (en Inglés)

Homology Modeling of Human Nk-1 Receptor and Docking Study: Structure Based Drug Design (en Inglés)

Formato

Libro Físico

Editorial

Lap Lambert Academic Publishing

Autor

Manish K. Gupta; Viney Kumar

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

ISBN13

9783659804205

Homology Modeling of Human Nk-1 Receptor and Docking Study: Structure Based Drug Design (en Inglés)

Manish K. Gupta; Viney Kumar (Autor) · Lap Lambert Academic Publishing · Tapa Blanda

Libro Nuevo Importado

Envío: 20 a 24 días háb.

$ 441.209$ 242.665

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 10 unidades

$ 242.665

¡Envío Gratis! Llega entre el 22 Jul y el 29 Jul a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Homology Modeling of Human Nk-1 Receptor and Docking Study: Structure Based Drug Design (en Inglés)"

Neurokinin-1 (NK-1) receptor regulates many biological functions related to cancer, such as tumor cell proliferation, angiogenesis and migration of tumor cells for invasion and metastasis. The NK-1 receptor antagonists specifically inhibit tumor cell proliferation, migration of the tumor cells and show antiangiogenic effect. Therefore, the development of NK-1 antagonists for the treatment of cancer is of current interest. The 3D structure of NK-1 is not available from protein data bank. This hampers the design of selective NK-1 antagonists. This book describes the homology modeling of the human NK-1 receptor using multiple templates to provide structural basis for the design of new NK-1 inhibitors and anticancer agents. The authors anticipate that the book will be very useful for the researchers who are working on the design and development of NK-1 receptor antagonists and anticancer agents.